Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Super-Sized semaglutide: could a 7.2 mg dose be a Game-Changer for obesity and diabetes?

NCT ID NCT05649137

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested a high 7.2 mg weekly dose of semaglutide (a drug already used for diabetes and weight loss) in 512 adults with obesity and type 2 diabetes. Participants received either the high dose, a lower dose, or a placebo, along with lifestyle counseling. The study measured weight loss and blood sugar control over 72 weeks to see if the higher dose provides greater benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
semaglutide (a once-weekly injection)
What this could lead to
If successful, this high dose of semaglutide could offer a more effective option for significant weight loss and better blood sugar control in people with obesity and type 2 diabetes.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The higher dose may cause more side effects like nausea or vomiting, and not everyone may achieve the same level of weight loss or blood sugar improvement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

512 people

The number who actually took part.

Started

Jan 2023

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female. * Age above or equal to 18 years at the time of signing informed consent. * BMI greater than or equal to 30.0 kilograms per square meter (kg/m\^2). * Diagnosed with type 2 diabetes (T2D) greater than or equal to 180 days prior to the day of screening. * History of at least one self-reported unsuccessful dietary effort to lose body weight. * HbA1c 7.0-10.0 percent (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as measured by central laboratory at screening. Exclusion Criteria: * A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds \[lbs\]) within 90 days before screening irrespective of medical records. * Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. * Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square meter (30 mL/min/1.73 m\^2) (less than 45 mL/min/1.73 m\^2 in participants treated with Sodium-glucose Cotransporter-2 \[SGLT2i\]) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus type 2 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes mellitus type 2 Obesity

Contacts and locations

Locations

  • AMC Community Endocrinology

    Albany, New York, 12203, United States

  • APDP - Associação Protectora dos Diabéticos de Portugal

    Lisbon, 1250-230, Portugal

  • ARS- Deland CRU

    DeLand, Florida, 32720, United States

  • Amarillo Med Spec LLP

    Amarillo, Texas, 79106, United States

  • Bajcsy-Zsilinszky Kórház

    Budapest, 1106, Hungary

  • Belinus Bt.

    Debrecen, Hajdú-Bihar, 4025, Hungary

  • Borbánya Praxis E.Ü. Kft.

    Nyíregyháza, Szabolcs-Szatmar Varmegye, 4405, Hungary

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Pomeranian Voivodeship, 81-338, Poland

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama, 36106, United States

  • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.

    Budapest, 1089, Hungary

  • DCC VII - Sofia EOOD, Endocrinology

    Sofia, 1233, Bulgaria

  • DCOL Ctr for Clin Res

    Longview, Texas, 75605, United States

  • DIABETOL, s.r.o.

    Prešov, 080 01, Slovakia

  • DIADA s.r.o.

    Bardejov, 08501, Slovakia

  • DIADA, s.r.o.

    Bardejov, 08501, Slovakia

  • Deepak Lakha

    Johannesburg, Gauteng, 1820, South Africa

  • Diab - Int, s.r.o.

    Bytča, 014 01, Slovakia

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • Dr N.K. Gounden Medical Centre

    Durban, KwaZulu-Natal, 4093, South Africa

  • Dr T Padayachee

    eMkhomazi, KwaZulu-Natal, 4170, South Africa

  • ENDOMED, s.r.o.

    Košice, 04013, Slovakia

  • Elligo Clin Res Centre

    Austin, Texas, 78704, United States

  • Fejér Megyei Szent György Oktatókórház

    Székesfehérvár, 8000, Hungary

  • Florida Inst For Clin Res LLC

    Orlando, Florida, 32825, United States

  • G.A. Research Associates Ltd.

    Moncton, New Brunswick, E1G 1A7, Canada

  • Hemant Makan

    Johannesburg, Gauteng, 1827, South Africa

  • Hope Clin Res & Wellness

    Conyers, Georgia, 30094, United States

  • Hospital da Luz Arrabida, S.A.

    Vila Nova de Gaia, 4400-346, Portugal

  • Hospital da Luz Lisboa, S.A.

    Lisbon, 1500-650, Portugal

  • IPSOMC - Dr. Georgi Marinov

    Burgas, 8000, Bulgaria

  • Jacksonville Ctr for Clin Res

    Jacksonville, Florida, 32216, United States

  • John Muir Physicians Network

    Concord, California, 94520, United States

  • Kresmed Sp. z o. o.

    Bialystok, Podlaskie Voivodeship, 15-481, Poland

  • Lausmed Kft.

    Baja, Bács-Kiskun county, 6500, Hungary

  • Lenmed Shifa Private Hospital

    Durban, KwaZulu-Natal, 4901, South Africa

  • MED-DIA CENTRUM s.r.o.

    Považská Bystrica, 01701, Slovakia

  • MED-TIMA Kft.

    Budapest, 1132, Hungary

  • MHAT - Blagoevgrad AD, Department of Internal Diseases

    Blagoevgrad, 2700, Bulgaria

  • MHAT Hadzhi Dimitar OOD

    Sliven, 8800, Bulgaria

  • MHAT Sveta Karidad EAD

    Plovdiv, 4004, Bulgaria

  • MHAT Sveti Panteleimon - Yambol AD

    Yambol, 8600, Bulgaria

  • Maxwell Centre

    Durban, KwaZulu-Natal, 4001, South Africa

  • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET

    Krakow, Lesser Poland Voivodeship, 31-261, Poland

  • Medi-Clinic Bloemfontein

    Bloemfontein, Free State, 9301, South Africa

  • Medical Center Viva Feniks OOD

    Dobrich, 9300, Bulgaria

  • Milestone Research

    London, Ontario, N5W 6A2, Canada

  • NBR Polska Tomasz Klodawski

    Warsaw, 00-710, Poland

  • NZOZ "CenterMed Lublin" Sp. z o.o.

    Lublin, Lublin Voivodeship, 20-044, Poland

  • NZOZ Przychodnia Specjalistyczna Medica

    Lublin, Lubelski, 20-538, Poland

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • New West Physicians PC

    Golden, Colorado, 80401, United States

  • Nova Scotia Hlth Halifax

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Ocean West Research Clinic

    Surrey, British Columbia, V3Z 2N6, Canada

  • Oviedo Medical Research, LLC

    Oviedo, Florida, 32765, United States

  • PANSTWOWY INSTYTUT MEDYCZNY MSWiA

    Warsaw, 02-507, Poland

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina, 27408, United States

  • Phoenix Pharma

    Port Elizabeth, Eastern Cape, 6001, South Africa

  • PlanIt Research, PLLC

    Houston, Texas, 77079, United States

  • Precise Clinical Solutions (Pty) Ltd

    Durban, KwaZulu-Natal, 4092, South Africa

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, L8L 5G4, Canada

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • Soweto Clinical Trial Centre

    Johannesburg, Gauteng, 1818, South Africa

  • Sugar Lakes Family Practice PA

    Sugar Land, Texas, 77479, United States

  • ULS De Matosinhos E.P.E.- Hospital Pedro Hispano

    Senhora Da Hora, Matosinhos, Matosinhos, 4464-513, Portugal

  • ULS De São João, E.P.E. - Hospital de São João

    Porto, 4200-319, Portugal

  • UMHAT Prof. Dr. Stoyan Kirkovich AD

    Stara Zagora, 6003, Bulgaria

  • UMHAT Pulmed OOD - Pazardzhik, Department of Internal Diseases

    Pazardzhik, 4400, Bulgaria

  • UT Southwestern Medical Center - Lingvay

    Dallas, Texas, 75390, United States

  • Unidade Local De Saúde De Lisboa Ocidental E.P.E. - Hospital Egas Moniz

    Lisbon, 1349-019, Portugal

  • Univ of Alabama Birmingham

    Birmingham, Alabama, 35222, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27514, United States

  • Uniwersyteckie Centrum Kliniczne SUM w Katowicach

    Katowice, 40-752, Poland

  • Velocity Clin Res, Dallas

    Dallas, Texas, 75230, United States

  • Velocity Clinical Research Westlake

    Los Angeles, California, 90057, United States

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, L8L 5G8, Canada

  • Wits Bara Clinical Trial Site

    Johannesburg, Gauteng, 2013, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.